Market Trends

The tech-heavy index's performance is likely to remain strong. It's also likely to remain volatile.

Three indexes, one identical decline. Oil above $105 is casting heavy shadows over Wall Street.

Today, Sept. 10, 2026, drone and defense stock AeroVironment jumps while broader markets fall as geopolitical tensions re-escalate.

The smartest investors may be preparing in a way most investors would not expect.

The president made the promise during the first day of the GOP midterm convention.

Stocks generally react poorly to higher interest rates. Does that mean you should adjust your portfolio?

Investors are worried that artificial intelligence will eventually have its dot-com bubble moment.

SCHO sticks to Treasuries with minimal volatility, while ISTB diversifies into corporate and mortgage debt for extra income. Which strategy fits your risk tolerance?

Will Warsh be able to prove that the fight against inflation is actually going to be fought again?

History says now is the time for investors to start preparing for volatility.

One fund offers broad sector exposure at 0.08% cost; the other concentrates on 30 biotech stocks with higher volatility but stronger recent returns.

FHLC captures the whole healthcare opportunity at rock-bottom cost. XPH narrows the bet to pharmaceuticals and charges significantly more for it.

Apple delivers $1,999 foldable iPhone, TSMC beats August revenue expectations, and more...

SCHE offers a cheaper, higher-yielding path into global growth while URTH delivers the steadier returns of developed markets at a higher price.

Higher yields on Treasury bonds could be a warning signal -- or a healthy sign.

Investors have been worried about the stock market's elevated valuation for years.

It's still a great option for the retail investor.

Fed Chair Kevin Warsh’s Jackson Hole speech and the August jobs report have tipped the scales decisively in favor of a rate hike.

IPOs get a lot of buzz, but they don't often pan out for investors.

Broad diversification and lower costs favor iShares, but Invesco's concentrated biotech bet delivered 47% returns in one year—at the cost of steeper drawdowns.